Email Alert RSS
Volume 9 Issue 3
. 
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2018  >  9(3): 251-255
Shan LI, Hui HUANG, Zuo-jun XU. Common Comorbidities in Patients with Idiopathic Pulmonary Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 251-255. doi: 10.3969/j.issn.1674-9081.2018.03.012
Citation: Shan LI, Hui HUANG, Zuo-jun XU. Common Comorbidities in Patients with Idiopathic Pulmonary Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 251-255. doi: 10.3969/j.issn.1674-9081.2018.03.012
shu

Common Comorbidities in Patients with Idiopathic Pulmonary Fibrosis

doi: 10.3969/j.issn.1674-9081.2018.03.012

  • Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: XU Zuo-jun Tel: 010-69155039, E-mail: xuzj@hotmail.com
  • Received Date: 2017-12-18
  • Publish Date: 2018-05-30
    Abstract
  • Idiopathic pulmonary fibrosis(IPF) is a progressive fatal disease of the lung with unknown etiology and limited treatment options. It is more common in men and the elderly aged over 50 years, which also have a high incidence of emphysema, lung neoplasms, and cardiovascular disease. IPF patients with comorbidities often have a worse prognosis than those with IPF alone. We write this article in reference to common comorbidities in patients with idiopathic pulmonary fibrosis to draw physicians' attention. Clinical physicians should know that much can be done to identify and alleviate symptoms of those comorbidities, and to potentially improve the overall quality of life of these patients.
    • FullText(HTML)
  • loading
    • References(40)
  • [1] Karampitsakos T, Tzilas V, Tringidou R, et al. Lung cancer in patients with idiopathic pulmonary fibrosis[J]. Pulm Pharmacol Ther, 2017, 45:1-10. doi:  10.1016/j.pupt.2017.03.016
    [2] Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis[J]. Chest, 2015, 147:157-164. doi:  10.1378/chest.14-0359
    [3] Watanabe A, Higami T, Ohori S, et al. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?[J].J Thorac Cardiovasc Surg, 2008, 136:1357-1363. doi:  10.1016/j.jtcvs.2008.07.016
    [4] Ono T, Hareyama M, Nakamura T, et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis:a single center experience[J].Radiat Oncol, 2016, 11:56. doi:  10.1186/s13014-016-0637-3
    [5] Iwata T, Yoshida S, Nagato K, et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis[J]. Surg Today, 2015, 45:1263-1270. doi:  10.1007/s00595-014-1071-5
    [6] Mediavilla-Varela M, Boateng K, Noyes D, et al. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts[J].BMC Cancer, 2016, 16:176. doi:  10.1186/s12885-016-2162-z
    [7] Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1):a phase 3, double-blind, randomised controlled trial[J]. Lancet Oncol, 2014, 15:143-155. doi:  10.1016/S1470-2045(13)70586-2
    [8] Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema:a distinct underrecognised entity[J]. Eur Respir J, 2005, 26:586-593. doi:  10.1183/09031936.05.00021005
    [9] Cottin V, Hansell DM, Sverzellati N, et al. Effect of emphysema extent on serial lung function in patients with idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2017, 196:1162-1171. doi:  10.1164/rccm.201612-2492OC
    [10] Sugino K, Ishida F, Kikuchi N, et al. Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone[J]. Respirology, 2014, 19:239-245. doi:  10.1111/resp.12207
    [11] Kohashi Y, Arai T, Sugimoto C, et al. Clinical Impact of Emphysema Evaluated by High-Resolution Computed Tomography on Idiopathic Pulmonary Fibrosis Diagnosed by Surgical Lung Biopsy[J]. Respiration, 2016, 92:220-228. doi:  10.1159/000448118
    [12] Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema:decreased survival associated with severe pulmonary arterial hypertension[J]. Chest, 2009, 136:10-15. doi:  10.1378/chest.08-2306
    [13] Dong F, Zhang Y, Chi F, et al. Clinical efficacy and safety of ICS/LABA in patients with combined idiopathic pulmonary fibrosis and emphysema[J]. Int J Clin Exp Med, 2015, 8:8617-8625. http://europepmc.org/articles/PMC4538025/
    [14] Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients:a systematic literature review[J]. Eur Respir J, 2015, 46:1113-1130. doi:  10.1183/13993003.02316-2014
    [15] Hayes D, Jr., Black SM, Tobias JD, et al. Influence of Pulmonary Hypertension on Patients With Idiopathic Pulmonary Fibrosis Awaiting Lung Transplantation[J]. Ann Thorac Surg, 2016, 101:246-252. doi:  10.1016/j.athoracsur.2015.06.024
    [16] Alkukhun L, Wang XF, Ahmed MK, et al. Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis[J]. Respir Med, 2016, 117:65-72. doi:  10.1016/j.rmed.2016.06.001
    [17] Idiopathic Pulmonary Fibrosis Clinical Research N, Zisman DA, Schwarz M, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis[J]. N Engl J Med, 2010, 363:620-628. doi:  10.1056/NEJMoa1002110
    [18] Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction[J]. Chest, 2013, 143:1699-1708. doi:  10.1378/chest.12-1594
    [19] Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis[J]. Sleep Breath, 2015, 19:385-391. doi:  10.1007/s11325-014-1033-6
    [20] Gille T, Didier M, Boubaya M, et al. Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis[J]. Eur Respir J, 2017, 49:1601934. doi:  10.1183/13993003.01934-2016
    [21] Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011, 183:788-824. doi:  10.1164/rccm.2009-040GL
    [22] Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis[J]. Eur Respir J, 2006, 27:136-142. doi:  10.1183/09031936.06.00037005
    [23] Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis[J]. Eur Respir J, 2012, 39:352-358. doi:  10.1183/09031936.00050911
    [24] Lee JS. The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis[J]. Clin Pulm Med, 2014, 21:81-85. doi:  10.1097/CPM.0000000000000031
    [25] Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis:an analysis of data from three randomised controlled trials[J]. Lancet Respir Med, 2013, 1:369-376. doi:  10.1016/S2213-2600(13)70105-X
    [26] Linden PA, Gilbert RJ, Yeap BY, et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation[J]. J Thorac Cardiovasc Surg, 2006, 131:438-446. doi:  10.1016/j.jtcvs.2005.10.014
    [27] Fulton BG, Ryerson CJ. Managing comorbidities in idiopathic pulmonary fibrosis[J]. Int J Gen Med, 2015, 8:309-318. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Doaj000004008806
    [28] Sprunger DB, Olson AL, Huie TJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease[J]. Eur Respir J, 2012, 39:125-132. doi:  10.1183/09031936.00041411
    [29] Dalleywater W, Powell HA, Fogarty AW, et al. Venous thromboembolism in people with idiopathic pulmonary fibr-osis:a population-based study[J]. Eur Respir J, 2014, 44:1714-1715. doi:  10.1183/09031936.00099614
    [30] Nathan SD, Barnett SD, Urban BA, et al. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients[J]. Chest, 2003, 123:1758-1763. doi:  10.1378/chest.123.5.1758
    [31] Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2012, 186:88-95. doi:  10.1164/rccm.201202-0314OC
    [32] Rochwerg B, Raghu G. Reply:Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?[J]. Am J Respir Crit Care Med, 2016, 193:811. doi:  10.1164/rccm.201601-0078LE
    [33] Hubbard RB, Smith C, Le JeuneI, et al. The association between idiopathic pulmonary fibrosis and vascular disease:a population-based study[J]. Am J Respir Crit Care Med, 2008, 178:1257-1261. doi:  10.1164/rccm.200805-725OC
    [34] Kim WY, Mok Y, Kim GW, et al. Association between idiopathic pulmonary fibrosis and coronary artery disease:a case-control study and cohort analysis[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2015, 31:289-296. http://www.ncbi.nlm.nih.gov/pubmed/25591140
    [35] Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis[J]. Respir Med, 2010, 104:1035-1041. doi:  10.1016/j.rmed.2010.02.008
    [36] Nathan SD, Weir N, Shlobin OA, et al. The value of computed tomography scanning for the detection of coronary artery disease in patients with idiopathic pulmonary fibrosis[J]. Respirology, 2011, 16:481-486. doi:  10.1111/j.1440-1843.2010.01919.x
    [37] Nielsen TD, Bahnson T, Davis RD, et al. Atrial fibrillation after pulmonary transplant[J]. Chest, 2004, 126:496-500. doi:  10.1378/chest.126.2.496
    [38] Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis[J]. Respir Med, 2009, 103:927-931. doi:  10.1016/j.rmed.2008.11.001
    [39] Enomoto T, Usuki J, Azuma A, et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis[J]. Chest, 2003, 123:2007-2011. doi:  10.1378/chest.123.6.2007
    [40] Kim YJ, Park JW, Kyung SY, et al. Clinical characteristics of idiopathic pulmonary fibrosis patients with diabetes mellitus:the national survey in Korea from 2003 to 2007[J]. J Korean Med Sci, 2012, 27:756-760. doi:  10.3346/jkms.2012.27.7.756
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (281) PDF downloads(344) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return